Treatment for Diffuse Large B-Cell Lymphoma (DLBCL)
Your DLBCL journey begins with initial treatment
RITUXAN, along with CHOP chemotherapy, can be used as initial treatment for DLBCL. The goal in using this combination of drugs is to improve your chances of survival.
In one study, patients who received RITUXAN (rituximab) plus CHOP chemotherapy spent an average of 2.9 years without their cancer advancing or the need for a change in therapy, compared with an average of 1.1 years for patients who received CHOP chemotherapy by itself. Adding RITUXAN to CHOP chemotherapy as initial therapy reduced the risk of death by 32% compared to receiving CHOP chemotherapy alone. These results were from a clinical trial and may not be the same as what you experience.
You will have up to 8 cycles, or rounds, of treatment. Each cycle will last 21 days. Treatment occurs on the first day of each cycle and is followed by 20 days of rest and recovery. This means that most people will complete their treatment in about 6 months.